One clinical trial investigating combination platinum-based doublet and IDH1 inhibitor therapies (cisplatin and gemcitabine plus ivosidenib) showed promising improvements of both median PFS (15.4 months, 95% CI 13.8-24) and OS (22.9, 95% CI 18.2-27) in patients with unresectable IDH1-mutated CCA. This evidence concerns the gene IDH1 and cholangiocarcinoma.